NY-REVIV
The DRIPBaR, recognized as the fastest-growing IV therapy franchise in the United States, has joined forces with REVIV, the global leader in IV therapy, marking a significant milestone for the industry. The partnership creates an unrivaled offering by bringing together the specialties of two industry heavyweights boasting over 200 locations across 6 continents, with plans to add thousands more locations in the coming years. The recent surge in demand for IV therapy presents enormous opportunities globally for the companies to redefine industry standards and spearhead the next era of IV therapy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301173923/en/
Ben Crosbie, CEO of The DRIPBaR and Sarah Lomas, Founder and CEO of REVIV Global, announce their exciting partnership. (Photo: Business Wire)
With an extensive pipeline boasting over 450 franchisees in the United States, The DRIPBaR's decision to integrate REVIV's proprietary technology-backed proposition, REVIV X, validates their commitment to provide personalized and precision nutrition solutions for their customers. This partnership empowers The DRIPBaR to leverage REVIV's 10 years of intellectual property and life science expertise, utilizing objective data from blood tests and DNA analysis to tailor IV therapies to individual needs. Through REVIV X, The DRIPBaR is poised to revolutionize the wellness landscape in the United States, offering patient-focused solutions that optimize health outcomes that will solidify its position as a leader in innovation.
Ben Crosbie, CEO of The DRIPBaR, expressed excitement in the collaboration, affirming, "By selecting REVIV as our strategic partner, we are unlocking personalized and precision capabilities for a more advanced product offering and customer experience. I’m very confident that leveraging REVIV's cutting-edge technology and expertise will accelerate the growth of our franchisees and position them ahead of industry norms. The REVIV X proposition, coupled with its accredited IV Academy training course, sets a global benchmark for excellence in our field, empowering us to maintain industry leadership."
Sarah Lomas, Founder and CEO of REVIV Global, highlighted the transformative impact of the partnership, stating, "The DRIPBaR's alignment with REVIV underscores our joint dedication to innovation and safety in the IV therapy market. As industry leaders, we are reshaping the future of wellness by offering personalized and precision nutrition solutions that cater to evolving customer needs. We will continue to develop our SaaS products to power the industry globally. After many years and significant investment in research and product development, it’s exciting to see such early validation and adoption for REVIV X."
This strategic alliance between REVIV and The DRIPBaR marks a pivotal moment in the IV therapy industry and multi-modality sectors, advancing the delivery of safe, effective, and tailored wellness solutions to customers across the United States and beyond. As the IV therapy market continues its rapid expansion, with safety and compliance at the forefront, REVIV X emerges as the solution of choice for IV therapy operators, creating the opportunity for existing multi-modality businesses to access REVIV's innovative solutions and maintain their position at the forefront of wellness innovation and industry standards.
About REVIV Global
REVIV Global is at the forefront of advanced wellness solutions, devoted to enriching health and vitality through state-of-the-art IV therapy treatments. With a widespread international footprint and a relentless pursuit of innovation, REVIV is spearheading a revolution in the wellness sector. Its distinctive technological platform empowers IV therapy providers to deliver personalized and precision solutions with unparalleled safety and efficiency.
About The DRIPBaR
The DRIPBaR, a pioneering brand in the realm of wellness, is poised to redefine the landscape of health and vitality through advances in IV therapy. With cutting-edge science and a strong commitment to safety, The DRIPBaR offers a transformative approach to cellular health and personalized care. Focusing on ever-evolving treatments and medical advancements, The DRIPBaR embraces a new era of wellness where rejuvenation, vitality, and optimized health converge.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301173923/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 14:00:00 CET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 14:00:00 CET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 14:00:00 CET | Press release
Financing will support the company’s expansion across EMEA to keep pace with AI and cloud demand Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 13:57:00 CET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom